MedTrace Logo

Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients

NCT00002445 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2005-06-24

No results posted yet for this study

Summary

The purpose of this study is to see if it is safe and effective to use IM862 to treat Kaposi's sarcoma (KS) in AIDS patients.

Conditions

  • Sarcoma, Kaposi
  • HIV Infections

Interventions

DRUG

IM862

Sponsors & Collaborators

  • Cytran

    lead INDUSTRY

Principal Investigators

  • Parkash Gill

  • David Scadden

  • Ariela Noy

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States
  • Australia
  • Belgium
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002445 on ClinicalTrials.gov